Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273623 · ClinicalTrials.gov registry record · Phase 4
The Jetstream G3™ Calcium Study
A Phase 4 study of Peripheral Arterial Disease, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
- 5
- Study locations
NCT01273623 is a Phase 4 study of Peripheral Arterial Disease that has completed, run by Boston Scientific Corporation. The registered enrollment target is 55 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01273623, a Phase 4 study of Peripheral Arterial Disease, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
- 5
- Study locations
Study Summary
To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).
Conditions Studied
Interventions
- DEVICE Jetstream Atherectomy System
Study Locations (5)
Arizona
- Arizona Heart Institute - Phoenix
Georgia
- Emory University - Atlanta
Michigan
- St. John Hopital - Detroit
Tennessee
- Mercy Medical Center - Knoxville
Wisconsin
- Wheaton Franciscan Healthcare - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01273623
The ClinicalTrials.gov registry entry for NCT01273623 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Jetstream Atherectomy System is the first listed.
NCT01273623 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT01273623 about?
NCT01273623 is a clinical study titled "The Jetstream G3™ Calcium Study". To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).
What is the current status of trial NCT01273623?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2011-01. Estimated completion is 2012-03.
What conditions does trial NCT01273623 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT01273623?
The interventions under investigation include: Jetstream Atherectomy System (DEVICE).
Who is sponsoring clinical trial NCT01273623?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01273623 being conducted?
This trial has 5 study locations across Arizona, Georgia, Michigan, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Vascular Trial Associated Registry Pilot
RECRUITING · Phase 4
-
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
ACTIVE NOT RECRUITING · Phase 4
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.